Citations

Showing 10 of 108152 citations.

Antibody-mediated Remyelination: Relevance to Multiple Sclerosis
Bieber, Allan J., Asakura, K., Warrington, Arthur E. , KAVERI, S-V, Sv, Kaveri, Rodriguez, Moses

Mayo Clinic

Multiple Sclerosis Journal | July 9, 2019 | Volume: 6 | Issue: 2_suppl | Pages: S1-S5

10.1177/135245850000602s01 Get It

Intravenous immunoglobulin (IVIG) is widely used for treatment of autoimmune neurological disorders and is currently in clinical trials as a therapy for multiple sclerosis. We have previously demonstrated that certain mouse monoclonal antibodies of the IgM isotype, promote significant remyelination when administered to mice with chronic Theiler's murine encephalomyelitis virus-induced demyelinating disease. These IgM antibodies bind to antigens expressed on oligodendrocytes. We now demonstrate that polyclonal human IgG (IVIG) and polyclonal human IgM also promote remyelination in this system. Although both polyclonal human IgG and IgM promote remyelination, IgM is more potent Polyclonal human IgM also differs from human IgG in its ability to bind strongly to antigens expressed in the CNS and by oligodendrocytes. We propose that polyclonal IgG and polyclonal IgM may function to promote remyelination by different mechanisms. IVIG may function based on its immunomodulatory activity, while the activity of IgM is critically dependent upon its reactivity with CNS antigens. This possibility has clear relevance to the use of antibodies as a therapy for multiple sclerosis, suggesting that combined treatment with antibodies exerting immunomodulatory activity, in concert with antibodies that function through direct binding to CNS antigens, may synergize to enhance the efficacy of the therapy.
Prognostic Implications of Diastolic Dysfunction Change in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Kim, Eun Kyoung , Park, Taek Kyu , Gwon, Hyeon‐Cheol , Oh, Jae K. , Park, Seung Woo , Hahn, Joo‐Yong , Lee, Joo Myung , Song, Young Bin , Chang, Sung‐A , Park, Sung‐Ji , Choi, Seung‐Hyuk , Lee, Sang‐Chol

Mayo Clinic

Circulation Journal | July 8, 2019 | Volume: 83 | Issue: 9 | Pages: 1891-1900

10.1253/circj.cj-19-0237 | PMID 31292309 Get It

Fetal surgery: how recent technological advancements are extending its applications
Vega, B. J. Reyes, Vega, Beatriz , Ruano, Rodrigo , Vega, Beatriz

Mayo Clinic

Expert Review of Medical Devices | July 8, 2019 | Volume: 16 | Issue: 8 | Pages: 643-645

10.1080/17434440.2019.1641404 | PMID 31283889 Get It

Prevalence of Atrial Fibrillation in Patients with Retinal Vessel Occlusion and Its Association: A Systematic Review and Meta-Analysis
Kewcharoen, Jakrin , Tom, Elysse S. , Wiboonchutikula, Chonlanan, Trongtorsak, Angkawipa , Wittayalikit, Chutikarn, Vutthikraivit, Wasawat , Prasitlumkum, Narut , Rattanawong, Pattara , Rattanawong, Pattara , Kewcharoen, Jakrin , Prasitlumkum, Narut

Mayo Clinic

Current Eye Research | July 8, 2019 | Volume: 44 | Issue: 12 | Pages: 1337-1344

10.1080/02713683.2019.1641826 | PMID 31283356 Get It

Poetic Science: Bidirectional Reflection in Science and Medicine
Brown, Sherry‐Ann

Mayo Clinic

The Permanente Journal | July 8, 2019 | Volume: 23 | Issue: 3 | Pages: No page available

10.7812/tpp/17-177 | PMID 31314715 Get It

Application of a 5 Marker Panel to the Routine Diagnosis of Peripheral T-Cell Lymphoma With T-Follicular Helper Phenotype
Basha, Basma, Bryant, Sandra C. , Vrana, Julie A., Reed, Katelyn A. , King, Rebecca L. , Rech, Karen L. , Feldman, Andrew L. , Shi, Min

Mayo Clinic

American Journal of Surgical Pathology | July 8, 2019 | Volume: 43 | Issue: 9 | Pages: 1282-1290

10.1097/pas.0000000000001315 | PMID 31283630 Get It

The 2017 World Health Organization update introduced a new category of nodal peripheral T-cell lymphoma with T-follicular helper phenotype (PTCL-TFH) defined by expression of at least 2 or 3 TFH markers. Our study assesses the utility of an immunohistochemical panel of 5 TFH markers (CD10, BCL6, PD-1, CXCL13, and ICOS) for identification of TFH phenotype in angioimmunoblastic T-cell lymphoma (AITL) and PTCL not otherwise specified (NOS). Immunohistochemical for the 5 markers was performed on 22 cases of AITL and 29 cases of PTCL-NOS. Cases were reviewed for morphologic features characteristic of AITL. All AITL cases showed expression of ≥2 TFH markers. This panel resulted in reclassification of 41% PTCL-NOS cases to PTCL-TFH. Positive percent agreement for the TFH phenotype is 97% for PD1, 94% for ICOS, 44% for CD10 and CXCL13, and 29% for BCL6. Negative percent agreement for TFH phenotype is 100% for CD10, BCL6, and CXCL13, 82% for ICOS and 71% for PD1. AITL cases were more likely than PTCL-TFH cases to contain expanded CD21-positive follicular dendritic cell meshworks, clear cell cytology and polymorphous inflammatory background; however, there was a significant (P<0.005) Kruskal-Wallis trend in all morphologic variables between the 3 groups suggesting a continuum from PTCL-NOS to PTCL-TFH to AITL. The median number of morphologic features of AITL also correlated significantly with number of TFH markers positive (Spearman coefficient ρ=0.759). In summary, the stain panel chosen will have an impact on cases classified as PTCL-TFH. This entity may exist along a spectrum between PTCL-NOS and AITL.
Diabetogenic Effects of Immunosuppression: An Integrative Analysis
Bhat, Mamatha , Pasini, Elisa , Das, Aninditee, Baciu, Cristina , Angeli, Marc , Humar, Atul , Watt, Kymberly D. , Allard, Johane P. , Bhat, Mamatha

Mayo Clinic

Transplantation | July 8, 2019 | Volume: 104 | Issue: 1 | Pages: 211-221

10.1097/tp.0000000000002815 | PMID 31283677 Get It

Background. Posttransplant diabetes mellitus (PTDM) affects up to 50% of solid organ transplant recipients and compromises long-term outcomes. The goal of this study was to investigate how immunosuppressants affect gene expression in a manner that increases diabetes risk, by performing integrative analysis on publicly available, high-throughput gene expression data. Methods. All high-throughput gene expression datasets of solid organ transplant recipients were retrieved from the Gene Expression Omnibus. Significantly dysregulated genes and pathways were determined, and those in common with type 2 diabetes were identified. THP-1 and HepG2 cells were exposed in vitro to tacrolimus, and validation of genes involved in insulin signaling and glucose metabolism was performed using specific arrays. These cells were then treated with the hypoglycemic agents, metformin, and insulin to assess for appropriate reversion of specific diabetogenic genes. Results. Insulin signaling and secretion were the most commonly dysregulated pathways that overlapped with diabetes in transplant recipients. KRAS, GRB2, PCK2, BCL2L1, INSL3, DOK3, and PTPN1 were among the most significantly upregulated genes in both immunosuppression and diabetes subsets and were appropriately reverted by metformin as confirmed in vitro. Conclusions. We discovered that the significantly dysregulated genes in the context of immunosuppression are implicated in insulin signaling and insulin secretion, as a manifestation of pancreatic β-cell function. In vitro validation confirmed key diabetes-related genes in the context of immunosuppression. Further analysis and in vitro validation revealed that metformin optimally reverts diabetogenic genes dysregulated in the context of immunosuppression. The optimal therapeutic management of posttransplant diabetes mellitus needs to be further investigated, taking into account the mechanistic impact of immunosuppressants.
An Unusual Case of Median Neuropathy: Application of Short Segmental Sensory Nerve Stimulation
Luetmer, Marianne T. , Laughlin, Ruple S.

Mayo Clinic

Journal of Clinical Neurophysiology | July 8, 2019 | Volume: 36 | Issue: 6 | Pages: 468-470

10.1097/wnp.0000000000000616 | PMID 31274708 Get It

Summary: A 55-year-old woman presented with an 18-month history of intermittent left-hand paresthesias affecting her first, second, and third digits. A small, immobile, nontender midline mass on the volar aspect of the left wrist was also present. Evaluation included normal routine nerve conduction studies and needle electromyography. An ultrasound was performed in the electromyography laboratory, verifying median nerve involvement of the mass within the proximal carpal tunnel. This finding guided the electromyographer to perform the unconventional technique of sensory nerve short segmental stimulation across the carpal tunnel, which confirmed focal slowing across the lesion, achieving electrodiagnostic confirmation of median nerve impairment. This case of atypical carpal tunnel syndrome due to a median nerve schwannoma demonstrates both the utility and specificity of short segmental sensory stimulation in some cases of median neuropathy at the wrist and the value of sonography in the electromyography laboratory.
Establishing Normal Values for F-Wave Latencies in Diagnosing Peripheral Neuropathies for the Pediatric Population
Sharma, Rishi , Sorenson, Eric J. , Ryan, Conor S. , Conlee, Erin M., Boon, Andrea J. , Laughlin, Ruple S.

Mayo Clinic

Journal of Clinical Neurophysiology | July 8, 2019 | Volume: 37 | Issue: 1 | Pages: 68-73

10.1097/wnp.0000000000000609 | PMID 31274707 Get It

Purpose: We present a unique technique applying F-wave latencies to assist in the diagnosis of peripheral neuropathy within the pediatric age group. Methods: We calculated an F-wave estimated deviance adjusted for limb length measurements, distal motor conduction velocity, and distal motor latencies. We compared the F-wave estimated deviance from the normal subjects with those with peripheral neuropathy (both axonal and demyelinating) to establish diagnostic accuracy in pediatric patients. Results: The normal range for the F-wave estimated deviance in the upper limb was −1 to +6 ms and in the lower limb was −8 to +5 ms. When compared with 82 subjects with peripheral neuropathy, there was a significant difference between the normal subjects and those with neuropathy (P values between 0.002 and 0.0005 for each of the individual nerves tested). Conclusions: The F-wave estimated deviance is independent of age and can be accurately applied to the electrodiagnostic testing of pediatric patients with suspected neuropathy.
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Carbone, Michele , Adusumilli, Prasad S. , Alexander, H. Richard , Baas, Paul, Bardelli, Fabrizio , Bononi, Angela , Bueno, Raphael , Felley‐Bosco, Emanuela , Galateau-Sallé, Françoise , Jablons, David M., Mansfield, Aaron S. , Minaai, Michael , Severson, David T. , Woodard, Gavitt A. , Yang, Haining , Pass, Harvey I. , Mansfield, Aaron S , Baas, Paul, de Perrot, Marc , Pesavento, Patricia A. , Rusch, Valerie W. , Taioli, Emanuela , Tsao, Anne S. , Zauderer, Marjorie G.

Mayo Clinic

CA: A Cancer Journal for Clinicians | July 8, 2019 | Volume: 69 | Issue: 5 | Pages: 402-429

10.3322/caac.21572 | PMID 31283845 Get It

Abstract Mesothelioma affects mostly older individuals who have been occupationally exposed to asbestos. The global mesothelioma incidence and mortality rates are unknown, because data are not available from developing countries that continue to use large amounts of asbestos. The incidence rate of mesothelioma has decreased in Australia, the United States, and Western Europe, where the use of asbestos was banned or strictly regulated in the 1970s and 1980s, demonstrating the value of these preventive measures. However, in these same countries, the overall number of deaths from mesothelioma has not decreased as the size of the population and the percentage of old people have increased. Moreover, hotspots of mesothelioma may occur when carcinogenic fibers that are present in the environment are disturbed as rural areas are being developed. Novel immunohistochemical and molecular markers have improved the accuracy of diagnosis; however, about 14% (high‐resource countries) to 50% (developing countries) of mesothelioma diagnoses are incorrect, resulting in inadequate treatment and complicating epidemiological studies. The discovery that germline BRCA1‐asssociated protein 1 ( BAP1 ) mutations cause mesothelioma and other cancers (BAP1 cancer syndrome) elucidated some of the key pathogenic mechanisms, and treatments targeting these molecular mechanisms and/or modulating the immune response are being tested. The role of surgery in pleural mesothelioma is controversial as it is difficult to predict who will benefit from aggressive management, even when local therapies are added to existing or novel systemic treatments. Treatment outcomes are improving, however, for peritoneal mesothelioma. Multidisciplinary international collaboration will be necessary to improve prevention, early detection, and treatment.